Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD | Market Cap | 315.42M +141.5% |
| Revenue (ttm) | n/a |
| Net Income | -34.08M |
| EPS | -0.34 |
| Shares Out | 116.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 315,588 |
| Open | 2.870 |
| Previous Close | 2.870 |
| Day's Range | 2.650 - 2.900 |
| 52-Week Range | 1.225 - 3.150 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+122.22%) |
| Earnings Date | Nov 12, 2026 |
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol fo... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRDL stock is "Strong Buy." The 12-month stock price target is $6.00, which is an increase of 122.22% from the latest price.
News
Cardiol Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $11 price target The firm believes the company’s lead candidate, CardiolRx, is “significantly de-risked” in the ongoing...
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics price target raised to $10 from $8 at Canaccord
Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy rating on the shares. The firm said the increase in its price…
Cardiol Therapeutics Registration statement: Q2 2026
Cardiol Therapeutics filed a registration statement on August 12, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics Registration statement: Q2 2026
Cardiol Therapeutics filed a registration statement on August 12, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics NASDAQ: CRDL is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describi...
Cardiol Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
A pivotal phase III trial is underway for an oral, non-immunosuppressive therapy targeting recurrent pericarditis, with strong efficacy signals and a robust trial design. Commercial plans focus on specialty distribution, competitive pricing, and expansion into heart failure and myocarditis.
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibroti...
Cardiol Therapeutics (CRDL) Publishes Phase II Study Findings in JAHA
Cardiol Therapeutics (CRDL) Publishes Phase II Study Findings in JAHA
Cardiol Therapeutics’ CardiolRx featured in Phase 2 pericarditis published trial
Cardiol Therapeutics (CRDL) announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association, or JAHA. The publication comes as the pivotal Phase…
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics In...
Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston
Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibroti...
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibroti...
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...
Cardiol Therapeutics Registration statement: Q1 2026
Cardiol Therapeutics filed a registration statement on May 11, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics Registration statement: Q1 2026
Cardiol Therapeutics filed a registration statement on May 11, 2026, providing details about a securities offering with the SEC.
Cardiol Therapeutics Slides: Corporate presentation
Cardiol Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% en...
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites
Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network
Cardiol Therapeutics (CRDL) announced the continued expansion of its pivotal Phase III MAVERIC trial in the U.S., with the planned activation of up to seven additional clinical centers. Patient enroll...
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Lang...
Cardiol Therapeutics Transcript: Study result
2023 was a pivotal year, highlighted by the phase III MAVERIC trial for pericarditis and landmark ARCHER trial results in myocarditis. Strong enrollment, new patent protections, and a robust pipeline position the company for significant growth and strategic partnerships.